{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
DarioHealth Corp.
Is DarioHealth Corp. overvalued or undervalued?
DarioHealth Corp. is considered a risky investment due to its significant losses and negative valuation metrics, including a Price to Book Value of 0.42 and an EV to EBITDA of -0.80, which contribute to its underperformance of -60.76% year-to-date compared to the S&P 500's 12.22%.
DarioHealth Corp. Stock Plummets to New 52-Week Low of $6.00
DarioHealth Corp. has reached a new 52-week low of USD 6.00, despite a remarkable one-year performance of 372.52%. The company faces challenges with negative EBITDA and a return on equity of -53.24%, while maintaining a market capitalization of USD 22 million and a low debt-to-equity ratio.
DarioHealth Corp. Hits New 52-Week Low at $6.58 Amid Financial Concerns
DarioHealth Corp. has reached a new 52-week low, reflecting significant stock volatility despite a strong one-year performance. The company, with a market capitalization of USD 22 million, faces challenges including negative return on equity and EBITDA, while maintaining a low debt-to-equity ratio, highlighting its financial complexities.
Is DarioHealth Corp. overvalued or undervalued?
As of May 11, 2016, DarioHealth Corp. is considered overvalued and risky, with troubling financial ratios and significant underperformance compared to peers and the S&P 500.
Is DarioHealth Corp. technically bullish or bearish?
As of June 20, 2025, the market trend has shifted to mildly bearish, driven by bearish daily moving averages and underperformance against the S&P 500, despite some mildly bullish indicators on longer time frames.
Who are in the management team of DarioHealth Corp.?
As of March 2022, the management team of DarioHealth Corp. includes Yoav Shaked (Independent Chairman), Erez Raphael (CEO), and several directors: Dennis Matheis, Adam Stern, Allen Kamer, Hila Karah, and Dennis McGrath. They are responsible for the company's strategic direction and governance.
What does DarioHealth Corp. do?
DarioHealth Corp. is a Digital Therapeutics company focused on integrated digital therapeutic interventions in the Pharmaceuticals & Biotechnology industry. As of March 2025, it reported net sales of $7 million and a net loss of $9 million, with a market cap of $30.72 million.
How big is DarioHealth Corp.?
As of Jun 18, DarioHealth Corp. has a market capitalization of 30.72 million, with net sales of 28.02 million and a net profit of -32.31 million over the latest four quarters. Shareholder's funds are reported at 72.02 million, and total assets amount to 118.88 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
